Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PRA, Amgen in Strategic Biosimilar Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

PRA, Amgen in Strategic Biosimilar Pact

PRA to serve as sole provider for biosimilar studies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PRA has entered into an agreement with Amgen for a series of Phase III studies to develop several biosimilar drugs on a worldwide basis. PRA will serve as the sole provider of CRO services for these studies. Amgen and PRA will work together to execute Phase III studies related to Amgen’s current biosimilar portfolio, as well as the anticipated scope of Amgen’s global biosimilar portfolio.

“This agreement reflects and confirms PRA’s commitment to providing full service support to our clients’ development pipelines,” said Kent Thoelke, PRA’s executive vice president of Scientific and Medical Affairs. “Our mission is to assist our clients across all phases of biotech drug development by combining therapeutic and operational expertise with local knowledge to help them meet their development goals. As such, this relationship represents a key milestone in PRA’s commitment to supporting our clients’ biosimilar development programs. Amgen is a blue chip company and a world leader with a global reputation for excellence in bringing biologic therapies to patients with grievous illnesses. PRA has a strong track record in executing our clients’ global registration trials and helping to bring new drugs to market. We are delighted to announce this strategic relationship with Amgen.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics